$44.69
0.902.04%
Last update: Oct 26, 7:45 PM
Genmab AS (GMAB) Stock Price, Quote, News & History
GMABNASDAQ
Genmab shares positive petosemtamab trial data across multiple solid tumors at ESMO and partners with Incyte on targeted colorectal therapy.
You can purchase shares of Genmab (NASDAQ:GMAB) through any online brokerage.
Other companies in Genmab’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Genmab has a consensus price target of $41.46.
The stock price for Genmab (NASDAQ: GMAB) is $44.98 last updated October 26, 2026 at 7:45 PM EDT.
There are no upcoming dividends for Genmab.
Genmab does not have any upcoming earnings scheduled.
There is no upcoming split for Genmab.
Genmab is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab...
